L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Trial details
- Registry ID
- NCT06788756
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLNCT06788756 | MBRX | Phase 2, Phase 3 | Recruiting | 2029-08Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |